Albert Lowe
Stock Analyst at Craig-Hallum
(3.08)
# 1,004
Out of 5,182 analysts
10
Total ratings
30%
Success rate
34.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $123.46 | +41.75% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $20.69 | +141.66% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $5.37 | +272.79% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $4.55 | +31.87% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.70 | +1,905.73% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.88 | +183.51% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $1.58 | +406.33% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.57 | +154.78% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.34 | +347.76% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $123.46
Upside: +41.75%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $20.69
Upside: +141.66%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $5.37
Upside: +272.79%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $4.55
Upside: +31.87%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.70
Upside: +1,905.73%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.88
Upside: +183.51%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $1.58
Upside: +406.33%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.57
Upside: +154.78%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.34
Upside: +347.76%